• ‘Opioid Of The Masses’ Used To Make Therapies For Neurodegenerative Diseases

    Bio-IT World | Taking a cue from Mother Nature, researchers from The University of Texas at El Paso are exploring the use of carbon nanoparticles synthesized from caffeic acid found in coffee grounds as a preventative or therapeutic agent for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Their work marks the first time caffeic acid has been used to create carbon quantum dots and the approach is not only economical and sustainable but also potentially interventional.

    Jan 24, 2024

  • Protein Signatures Of Organ Aging Could Aid Disease Prevention Efforts

    Bio-IT World | Stanford Medicine investigators are leading the development of a test measuring organ-specific proteins in the blood as a simple and sensible way to estimate biological age. Among the potential applications are screening people for conditions such as heart failure and Alzheimer’s disease, personalizing the intervention they’re prescribed, and signaling sooner the efficacy of investigational drugs based on how well they rejuvenate certain organs.

    Jan 23, 2024

  • Research Suggests New Immunopreventive Approach To Tackling Cancer

    Bio-IT World | The lifetime probability of being diagnosed with an invasive cancer is estimated to be roughly 40% for both men and women, and there’s a strong possibility that they are all, in some sense, preventable. Scientific evidence suggests that the body’s immune system copes with the “internal danger” of tumor development the same way it deals with the external threat of infectious diseases.

    Jan 18, 2024

  • JP Morgan Healthcare on Acquisitions, AI Advancements, More

    Bio-IT World | At this year’s JP Morgan Healthcare conference, biotech and diagnostic companies and experts provided overviews of 2023 accomplishments and their goals for 2024. We’ve covered presentations by NVIDIA, Regeneron, Illumina, Pacific Biosciences, and Oxford Nanopore in depth. Here we list highlights from Pfizer, Moderna, Eli Lilly, Thermo Fisher, and more.

    Jan 17, 2024

  • Oxford Nanopore at JP Morgan: Native DNA Advantage

    Bio-IT World | CEO Gordan Sanghera gave Oxford Nanopore’s first live presentation at the JP Morgan Healthcare Conference last week. He highlighted his platforms accuracy and the company’s consumable growth.

    Jan 16, 2024

  • PacBio at JP Morgan: Revio, Onso, Three Sequencing Platforms in Development

    Bio-IT World | Christian Henry, President and CEO of Pacific Biosciences, was unabashedly cheerful at the JP Morgan Healthcare Conference on Wednesday afternoon when he gave the updates for PacBio. “2023 absolutely exceeded our expectations,” he said, basking in two platform launches, strong consumable growth, and three new platforms in development.

    Jan 12, 2024

  • Illumina at JP Morgan: Tighter Focus, Consumable Growth, Short Read Market

    Bio-IT World | CEO Jacob Thaysen presented Illumina’s updates yesterday at the JP Morgan Healthcare Conference. 2023 has been an eventful year for the sequencing pioneer with December’s announcement that Illumina would divest GRAIL; Francis deSouza, Illumina’s former CEO, stepping down in June; and $175M in cost cuts over the course of 2023 which included headcount reductions and major real estate changes. Thaysen presented Illumina at a turning point.

    Jan 10, 2024

  • The LOWE Down on Recursion’s New LLM Orchestration Work Engine from JP Morgan

    Bio-IT World | Chris Gibson, CEO of Recursion, launched a live demo of Recursion’s new large language model orchestration work engine, LOWE, yesterday at the JP Morgan Healthcare Conference. The tool is the next step toward Recursion’s goal of autonomous drug discovery.

    Jan 9, 2024

  • NVIDIA at JP Morgan: Generative AI and the Computer Aided Drug Design Tipping Point

    Bio-IT World | Drug design is at a tipping point, Kimberly Powell, vice president of Healthcare for NVIDIA, argued in her Monday morning presentation at the JP Morgan Healthcare Conference. “Two necessary conditions have arrived for drugs: digitizing biology and being able to represent it in a computer. We have the perfect conditions to see a massive expansion of this computer-aided drug discovery industry,” she said. And generative AI is the class of tools that will facilitate it.

    Jan 8, 2024

  • Power of Supercomputing and AI: Revolutionizing Allosteric Drug Discovery

    Bio-IT World | Driven by advancements in technology and data accessibility, computational methods and artificial intelligence (AI) have seen remarkable growth this past decade. This surge has ushered in a new era of problem-solving across a plethora of industries and domains.

    Jan 5, 2024

  • Top Stories from 2023: Spatial Biology, Innovative Practices, Generative AI, More

    Bio-IT World | Spatial biology, large language models, and new informatics tools. Bio-IT is exploring how AI fits into workstreams, still wrangling with data management challenges, and shaping discovery for the new era. Here are the top stories from Bio-IT World as well as thought leaders in the industry.

    Jan 4, 2024

  • Trendspotting: What’s Coming for Biotech in 2024

    Bio-IT World | To kick off the New Year, we spoke with leaders and experts in the Bio-IT community about their predictions for 2024.

    Jan 3, 2024

  • Genomenon Launches Classification Service, Medidata’s New Research Alliance, New Devices, Platforms, More

    Bio-IT World | Genomenon launched Genomenon Curate-Pro variant classification service; Medidata launches the Medidata Research Alliance; Edinburgh Innovations has announced a novel 3D printed device that could replace the need for drug and chemical safety testing on animals; and more.

    Dec 28, 2023

  • Follow the Money: AI For Drug Discovery, Small Molecule Therapeutics, Multi-Omics Platform for Women’s Reproductive Immunotherapies, More

    Bio-IT World | Sanofi enters a multi-year research collaboration with French pharmatech company Aqemia; Apple Tree Partners will expand its portfolio company Deep Apple Therapeutics to rapidly discover novel small molecule therapeutics for high-value targets through virtual screening of AI-generated virtual libraries; Freya Biosciences intends to advance their multi-omics data science platform; and more.

    Dec 27, 2023

  • ‘Reverse Metabolomics’ Enables Biological Discoveries From Repository Data

    Bio-IT World | In a turnaround of the usual metabolomics study approach, University of California San Diego scientists are homing in on the microbial-produced molecules that interact with cells and affect human health. A couple million such molecules are likely awaiting discovery in this fashion.

    Dec 21, 2023

  • NIH Program Tackles Bottlenecks In ‘Wild West’ Field Of exRNA Biology

    Bio-IT World | Driven by advancements in technology and data accessibility, computational methods and artificial intelligence (AI) have seen remarkable growth this past decade. This surge has ushered in a new era of problem-solving across a plethora of industries and domains.

    Dec 20, 2023

  • Living Biobank Of Brain Metastasis Samples Enabling ‘Personalized Medicine 2.0’

    Bio-IT World | Driven by advancements in technology and data accessibility, computational methods and artificial intelligence (AI) have seen remarkable growth this past decade. This surge has ushered in a new era of problem-solving across a plethora of industries and domains.

    Dec 19, 2023

  • Illumina to Divest GRAIL Business by Q2 2024

    Bio-IT World | On Sunday, Illumina announced that the company will divest GRAIL.

    Dec 17, 2023

  • Making Data Storage More Secure, More Flexible and Less Expensive for Medical and Scientific Applications

    Bio-IT World | One of the major side effects of the massive increase in the use of artificial intelligence (AI) for basic research, translational research, clinical research, pharmaceutical development, and patient care is the tsunami of data that will be created.

    Dec 15, 2023

  • Worm-Derived Drugs May One Day Treat Allergic and Autoimmune Diseases

    Bio-IT World | The development of antibiotics for treating tuberculosis in the 1940s eventually closed the doors of high-altitude sanitoriums that had long been the best therapeutic option for millions of patients. In much the same way, researchers at the Buck Institute for Research on Aging hope to one day eliminate the need to admit people suffering from Alzheimer’s, Parkinson’s disease, and other age-related phenomena to a geriatric or psychiatric hospital.

    Dec 13, 2023